Skip to main content
. 2017 Dec 8;52(2):119–124. doi: 10.1007/s13139-017-0496-3

Table 2.

Impact on post-operative 68Ga-DOTA-peptide PET/CT on staging and management (n = 36)

Impact on stage 19 (52.8%)
 Upstaging
 Downstaging
10
9 (including 2 false negatives)
Impact on therapy 20 (55.6%)
 Omit further Tx
 Start cold octreotide
 Re-surgery
 Palliative RT
6
11
2
1
No impact on therapy 11 (30.6%)
Unknown impact because lost to follow-up 5 (13.9%)